Glympse Bio, a Cambridge, Mass.-based biotechnology company, closed a $46.7m Series B financing.
The round was led by Section 32 and includes new investors Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, and Catalio Capital Management, as well as existing investors, including LS Polaris Innovation Fund, ARCH Venture Partners, CRV, GreatPoint Ventures, Gilead Sciences, and others also participated. In connection with the financing, Steven Kafka, Ph.D., Managing Partner at Section 32, and George Zachary, General Partner at CRV, will join the Glympse Board of Directors. Cayce Denton, Director at Temasek, and Andrew Perlman, Managing Partner at GreatPoint Ventures, will join the Board as Observers.
The company intends to use the funds for the continued development of its novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases.
Founded in 2015 and led by Caroline J. Loew, Ph.D., President and Chief Executive Officer, and Wendy Winckler, Ph.D., Chief Scientific Officer, Glympse Bio aims to transform the measurement of disease progression in vivo using bioengineered, tunable sensors that are designed for each protease-mediated disease. In October 2019, the company announced a strategic collaboration with Gilead Sciences to evaluate the technology as both a diagnostic and prognostic tool.
Glympse Bio is an MIT spin-out from the laboratory of renowned bioengineer, Dr. Sangeeta Bhatia.